Medical Xpress February 14, 2025
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily eye drops to treat glaucoma, a leading cause of blindness.
A team led by Molly Shoichet, a professor in the department of chemical engineering and applied chemistry and the Institute of Biomedical Engineering, used colloidal drug aggregates (CDAs) to modify the effects of a small-molecule glaucoma drug.
This new approach, described in a paper in the journal Advanced Materials, prolongs the drug’s effect from six hours when it is delivered via an eye drop to up to seven weeks with a single, non-invasive injection under the eyelid.
“Eye drops are the most common treatment for glaucoma, but they come...
Today's Sponsors
Today's Sponsor